Lumiliximab
Lumiliximab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target low affinity immunoglobulin epsilon Fc receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | LUMILIXIMAB |
INN | lumiliximab |
Description | Lumiliximab (chimeric mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2109151 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB06162 |
UNII ID | 8Z13S29R5A (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
FCER2
FCER2
Organism
Homo sapiens
Gene name
FCER2
Gene synonyms
CD23A, CLEC4J, FCE2, IGEBF
NCBI Gene ID
Protein name
low affinity immunoglobulin epsilon Fc receptor
Protein synonyms
BLAST-2, C-type lectin domain family 4 member J, C-type lectin domain family 4, member J, CD23, CD23 antigen, Fc fragment of IgE receptor II, Fc fragment of IgE, low affinity II, receptor for (CD23), Fc-epsilon-RII, FcepsilonRII, Immunoglobulin E-binding factor, immunoglobulin epsilon-chain, Lymphocyte IgE receptor
Uniprot ID
Mouse ortholog
Fcer2a (14128)
low affinity immunoglobulin epsilon Fc receptor (P20693)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 121 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
20 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more